Mycapssa Approval Status
- FDA approved: No
- Brand name: Mycapssa
- Generic name: octreotide
- Company: Chiasma, Inc.
- Treatment for: Acromegaly
Mycapssa (octreotide) is an oral formulation of the somatostatin analog octreotide (currently available as an injection) in development for the treatment of acromegaly.
On April 15, 2016, Chiasma, Inc. announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application for Mycapssa (octreotide) capsules for the maintenance treatment of adult patients with acromegaly. The FDA issues CRLs to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.
Development Status and FDA Approval Process for Mycapssa
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.